Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene

Pharmacogenomics Journal

Volumn 3, Issue 3, 2003, Pages 169-177

  Cornish, V A ^a   Pinter, K ^a   Boukouvala, S ^a   Johnson, N ^a   Labrousse, C ^a   Payton, M ^a   Priddle, H ^b,c   Smith, A J H ^b   Smith, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Arylamine N acetyltransferase; Folate; Knockout; Mouse; Teratology

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISOENZYME; XENOBIOTIC AGENT;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; GENE DISRUPTION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC ANALYSIS; GENETIC LINKAGE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REDUNDANCY ANALYSIS; TERATOLOGY; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; XENOBIOTIC METABOLISM;

AMINO ACID TRANSPORT SYSTEMS; ANIMALS; CARRIER PROTEINS; CROSSES, GENETIC; FEMALE; GENE TARGETING; INBREEDING; LIVER; MALE; MICE; MICE, INBRED A; MICE, INBRED C57BL; MICE, KNOCKOUT;

ANIMALIA; MUS MUSCULUS;

EID: 0037481687     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500170     Document Type: Article

References (45)

1. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79.
2. Upton A, Johnson N, Sandy J, Sim E. Arylamine N-acetyltransferases - of mice, men and microorganisms. Trends Pharmacol Sci 2001; 22: 140-146.
3. Le Marchand L, Hankin JH, Wilkens LR, Pierce LM, Franke A, Kolonel LN et al. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 1259-1266.
4. Firozi PF, Bondy ML, Sahin AA, Chang P, Lukmanji F, Singletary ES et al. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis 2002; 23: 301-306.
5. Golka K, Prior V, Blaszkewicz M, Bolt HM. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett 2002; 128: 229-241.
6. Varzim G, Monteiro E, Silva R, Pinheiro C, Lopes C. Polymorphisms of arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility. ORL J Otorhinolaryngol Relat Spectros 2002; 64: 206-212.
7. Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid acetylation in man. BMJ 1960; 2: 485-491.
8. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM, McManus ME. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci 2000; 54: 19-29.
9. Derewlany LO, Knie B, Koren G. Arylamine N-acetyltransferase activity of the human placenta. J Pharmacol Exp Ther 1994; 269: 756-760.
10. Smelt VA, Upton A, Adjaye J, Payton MA, Boukouvala S, Johnson N et al. Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum Mol Genet 2000; 9: 1101-1107.
11. Pacifici GM, Bencini C, Rane A. Acetyltransferase in humans: development and tissue distribution. Pharmacology 1986; 32: 283-291.
12. Minchin RF. Acetylation of para-aminobenzoylglutamate, a folate catabolite, by recombinant human NAT and U937 cells. Biochem J 1995; 307: 1-3.
13. Upton AS, Mushtaq V, Aplin A, Johnson R, Mardon N, Sim H et al. Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancy. Biochim Biophys Acta 2000; 1524: 143-148.
14. Kelly SL, Sim E. Arylamine NAT in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro. Biochem J 1994; 302: 347-353.
15. Fakis G, Boukouvala S, Buckle V, Payton M, Denning C, Sim E. Chromosome mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: identification of a novel upstream noncoding exon for murine Nat2. Cytogenet Cell Genet 2000; 90: 134-138.
16. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990; 9: 193-203.
17. Fretland AJ, Doll MA, Gray K, Feng Y, Hein DW. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens. Toxicol Appl Pharmacol 1997; 142: 360-366.
18. Payton M, Smelt V, Upton A, Sim E. A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. Biochem Pharmacol 1999; 58: 779-785.
19. Estrada L, Kanelakis KC, Levy GN, Weber WW. Tissue- and gender-specific expression of N-acetyltransferase 2 (Nat2 ) during development of the outbred mouse strain CD-1. Drug Metab Dispos 2000; 28: 139-146.
20. Mitchell MK, Futscher BW, McQueen CA. Developmental expression of N-acetyltransferases in C57BI/6 mice. Drug Metab Dispos 1999; 27: 261-264.
21. Stanley LA, Copp AJ, Pope J, Rolls S, Smelt V, Perry VH et al. Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. Teratology 1998; 58: 174-182.
22. Boukouvala S, Price N, Sim E. Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. Pharmacogenetics 2002; 12: 385-394.
23. Martell K, Vatsis K, Weber W. Molecular genetic basis of rapid and slow acetylation in mice. Mol Pharmacol 1991; 40: 218-227.
24. Martell K, Levy G, Weber W. Cloned mouse N-acetyltransferases: enzymatic properties of expressed Nat-1 and Nat-2 gene products. Mol Pharmacol 1992; 42: 265-272.
25. Estrada-Rodgers L, Levy G, Weber W. Substrate selectivity of mouse N-acetyltransferases 1,2 and 3 expressed in Cos-1 cells. Drug Metab Dispos 1998; 26: 502-505.
26. Nehls M, Kyewski B, Messerle M, Waldschutz R, Schuddekopf K, Smith AJ et al. Two genetically separable steps in the differentiation of thymic epithelium. Science 1996; 272: 886-889.
27. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999; 58: 1759-1764.
28. Copp AJ, Greene ND. Neural tube defects: prevention by folic acid and other vitamins. Indian J Pediatr 2000; 67: 915-921.
29. Shaw GM, Lammer EJ, Wasserman CR, O'Malley CD, Tolarova MM. Risks of orofacial clefts in children born to women using multi-vitamins containing folic acid periconceptionally. Lancet 1995; 346: 393-396.
30. Karolyi J, Erickson RP, Liu S, Killewald L. Major effects on teratogen-induced facial clefting in mice determined by a single genetic region. Genetics 1990; 126: 201-205.
31. Lammer EJ, Iovannisci DM, Shaw GM. Oral Clefts, Maternal Smoking and N-acetyltransferase Genes. Eynsham Hall: Oxford, UK, 2001.
32. Erickson RP, Mogan CT, McQueen CA. Mouse Red Blood Cell Folate Levels and Nat2 Variation. Eynsham Hall: Oxford, UK, 2001.
33. Sim E, Pinter K, Mushtaq A, Upton A, Sandy J, Noble M. Arylamine N-acetyltransferases - a pharmacogenomic approach to drug metabolism and endogenous function. Biochem Soc Trans 2003 (In press).
34. Gonzalez FJ. The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol Lett 2001; 120: 199-208.
35. Bourget P, Roulot C, Fernandez H. Models for placental transfer studies of drugs. Clin Pharmacokinet 1995; 28: 161-180.
36. Hakkola J, Pelkonen O, Pasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 1998; 28: 35-72.
37. Liang HC, Li H, McKinnon RA, Duffy JJ, Potter SS, Puga A et al. Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. Proc Natl Acad Sci USA 1996; 93: 1671-1676.
38. Smith AJ, De Sousa MA, Kwabi-Addo B, Heppell-Parton A, Impey H, Rabbitts P. A site-directed chromosomal translocation induced in embryonic stem cells by Cre-IoxP recombination. Nat Genet 1995; 9: 376-385.
39. Smith AG. Culture and differentiation of embryonic stem cells. J Tissue Culture Methods 1991; 13: 89-94.
40. Robertson EJ. Teratocarcinomas and Embryo Derived Stem Cells: A Practical Approach. IRL Press: Oxford, 1987.
41. McClive PJ, Sinclair AH. Rapid DNA extraction and PCR-sexing of mouse embryos. Mol Reprod Dev 2001; 60: 225-226.
42. Stanley LA, Coroneos E, Cuff R, Hickman D, Ward A, Sim E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem 1996; 44: 1059-1067.
43. Sinclair J, Delgoda R, Noble M, Jarmin S, Goh N, Sim E. Purification, characterisation and crystallisation of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium. Prot Exp Purific 1998; 12: 371-380.
44. Smelt VA, Mardon HJ, Sim E. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1 10 and NAT2 4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacol Toxicol 1998; 83: 149-157.
45. Hogan B, Beddington R, Costantini F, Lacy E. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor: New York, 1994.